Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) — Cash Flow-to-Debt Ratio
Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) has a Cash Flow-to-Debt Ratio of -0.02x as of December 2025, meaning its operating cash flow of $-314.86K could theoretically repay 0% of its total liabilities ($17.80 Million) in one year. See working capital to net assets of Drugs Made In America Acquisition II Cor to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Drugs Made In America Acquisition II Corp. Ordinary Shares Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for Drugs Made In America Acquisition II Corp. Ordinary Shares across 2 annual periods. Also explore DMII net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Drugs Made In America Acquisition II Corp. Ordinary Shares (2024–2025)
Year-by-year debt coverage analysis for Drugs Made In America Acquisition II Corp. Ordinary Shares. For market capitalisation and broader financial context, see DMII stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.06x | $-1.02 Million | $17.80 Million | ▲ +92.5% |
| 2024 | -0.76x | $-194.30K | $254.78K | — |